

AMENDMENTS TO THE SPECIFICATION

Page 1, after the title and before the first paragraph of the specification, please insert the following heading and paragraph as follows:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a National Stage of International Application No. PCT/EP05/50888, filed March 1, 2005, which claims benefit of U.S. Provisional Application No. 60/549,219, filed March 2, 2004 and U.S. Provisional Application No. 60/623,481, filed October 29, 2004, all of which are incorporated by reference in their entirety.

Change(s) applied
to document,
/M.J.D./
8/4/2011

Replace the paragraph on page 1, lines ²⁷~~26~~-30, with the following:

With more therapeutic options becoming available over time, resistance testing is expected to play an important role in the management and treatment of disease and the development of individualized treatment regimes [see e.g. ~~Haulbrich~~^{Haubrich} et al. JAIDS, 2001, 26S1, S51-S59].

Replace the paragraph on page 7, lines 15-25, with the following:

In a preferred embodiment, the PSS may be calculated based on preliminary clinical cut-offs which are determined as described. The concept of PSS is discussed in detail by DeGruttola et al. (Antiviral Therapy 2000; 5:41-48). In addition, the concept of continuous PSS as a variation of PSS is discussed by [[Bosch]]^{Allison} et al. (AIDS 2003, 17:1-9); Katzenstein et al. (AIDS 2003; 17:821-830); and Haubrich et al. ("Delavirdine Hypersusceptibility (DLV HS): Virological Response and Phenotypic Cut-Points--Results from ACTG 359"; 11th Conference on Retroviruses and Opportunistic Infections held on 8-11 Feb. 2004 in San Francisco, Calif.,